Tag: Triguard 3

Encouraging outcomes observed in Europe for the TriGUARD 3™ Cerebral Embolic Protection Device During Transcatheter Heart Procedures

TAMPA, Fla., Oct. 27, 2021 /PRNewswire/ — Keystone Heart Ltd., a Venus Medtech Company, today announced a key milestone in Europe with the TriGUARD 3 Cerebral Embolic Protection (CEP) Device. The device was granted CE mark in March of 2020 and, since launch, utilized in fourteen countries […]

Keystone Heart, A Venus Medtech Company, Announces First Commercial Case Performed Worldwide with the TriGUARD 3™ Cerebral Embolic Protection Device

TAMPA, Fla., July 29, 2020 /PRNewswire/ — Keystone Heart, LTD., a medical device innovator driven to redefine the standard of structural heart care, today announced completion of the first worldwide commercial case using the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device. Pieter Stella, MD, […]

Keystone Heart Ltd Announces First Enrollment in REFLECT Phase II incorporating TriGUARD 3™ Cerebral Embolic Protection device

CAESAREA, Israel and TAMPA, Fla., May 31, 2018 /PRNewswire/ — Keystone Heart Ltd., the leading medical device company focused on providing complete cerebral protection for patients undergoing cardiac procedures, today announced the launch of Phase II of the REFLECT trial to evaluate […]

Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures

NEWS PROVIDED BY Keystone Heart Ltd.  Aug 01, 2017, 13:06 ET CAESAREA, Israel and TAMPA, Fla., Aug. 1, 2017 /PRNewswire/ — Keystone Heart Ltd., an emerging medical device company focused on developing cerebral protection devices for patients undergoing cardiac procedures, today announced plans to initiate clinical […]